Annual Information Update

RNS Number : 6906B

Hikma Pharmaceuticals Plc

05 April 2013

 



Annual Information Update

London, 5 April 2013.  In accordance with Prospectus Rule 5.2, Hikma Pharmaceuticals PLC ("Hikma" or "the Company") (LSE: HIK) sets out below a summary of the information which has been published or made available to the public over the period. The information referred to in this Update was up to date at the time the information was published, but some information may now be out of date.

Stock Exchange Announcements

Announcements made by the Company via RNS, a Regulatory Information Service, may be viewed and downloaded from the Company's market news section on the London Stock Exchange website at (http://www.londonstockexchange.com/prices-and-news/stocks/stocks-and-prices.htm) or from the press releases page on the Company's website at (http://www.hikma.com/investorrelations/rns/). The Stock Exchange announcements made during the period were:

Date	Headline
25/03/2013	Director/PDMR Shareholding
13/03/2013	Preliminary Results
01/03/2013	Response to unsolicited enquiries
21/01/2013	Additional Listing
09/01/2013	Acquisition
03/01/2013	Total Voting Rights
27/12/2012	Holding(s) in Company
13/12/2012	Product Launch
27/11/2012	Building Public Trust Awards - Highly Commended
12/11/2012	Total Voting Rights
02/11/2012	Interim Management Statement
01/11/2012	Holding(s) in Company
11/10/2012	Injectables Analyst and Investor Day USA
10/10/2012	Blocklisting Interim Review
10/10/2012	Total Voting Rights
04/10/2012	Dividend Declaration
16/08/2012	Half Yearly Report
08/08/2012	Holding(s) in Company
06/07/2012	Total Voting Rights
03/07/2012	Holding(s) in Company
29/06/2012	Director/PDMR Shareholding
25/06/2012	Director/PDMR Shareholding
21/06/2012	Director/PDMR Shareholding
06/06/2012	Total Voting Rights
18/05/2012	Director/PDMR Shareholding
17/05/2012	Result of AGM
17/05/2012	Interim Management Statement
01/05/2012	Holding(s) in Company
20/04/2012	Holding(s) in Company
16/04/2012	Annual Information Update
13/04/2012	Annual Financial Report & AGM Notice

All of the above announcements were also made by the Company via the Nasdaq Dubai stock exchange CANDI system.  These announcements may be viewed and downloaded from the Nasdaq Dubai website (www.candi.nasdaq.com). 

Documents filed with the Financial Services Authority

The Company has filed the following documents with the Financial Services Authority ("FSA") visa the National Storage Mechanism over the previous 12 months.  These documents are available at http://www.hemscott.com/nsm.do or at the Company's registered office.

Date	Document
13 April 2012	Annual Report and Accounts 2011
13 April 2012	Notice of 2012 Annual General Meeting
13 April 2012	Proxy forms for the 2012 Annual General Meeting

Documents filed with Companies House

The Company submitted filings to the Registrar of Companies in England and Wales as detailed in the table below. 

Date Filed	Form	Description
12/11/2012	SH01	Statement of Capital GBP 19,697,811
10/10/2012	SH01	Statement of Capital GBP 19,697,141
07/09/2012	AR01	Annual Return, No Member List
09/07/2012	SH01	Statement of Capital GBP 19,686,391
15/06/2012	RES10	Authorised Allotment of Shares and Debentures
15/06/2012	AA	Group of Companies' Accounts made up to 31/12/11
06/06/2012	SH01	Statement of Capital GBP 19,682,241
21/05/2012	RES10	Authorised Allotment of Shares and Debentures
11/04/2012	AP03	Secretary Appointed, Peter Alexander Speirs
11/04/2012	TM02	Secretary Appointment Terminated, Henry Knowles

Copies of all these documents may be obtained from Companies House, Crown Way, Maindy, Cardiff CF14 3UZ or, if you are a registered user, they may be viewed and downloaded using Companies House Direct at www.direct.companieshouse.gov.uk.

Further Information

Copies of all documents can be obtained from the Company at the registered office which is located at 13 Hanover Square, London W1S 1HW.

Peter Speirs

Company Secretary
5 April 2013

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC
Peter Speirs Company Secretary	[phone]

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2012, Hikma achieved revenues of $1,108.7 million and profit attributable to shareholders of $100.3 million.

 

END

 

 

AIUBELFBXZFBBBB